BIRC5 immunotherapy-related clinical trials have been applied in patients with colorectal cancer (Tsuruma et al., 2004), malignant glioma (Fenstermaker et al., 2016), and melanoma (Becker et al., 2012). The gene discussed is BIRC5; the disease is malignant glioma.